Compare AMTX & BMEA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AMTX | BMEA |
|---|---|---|
| Founded | 2005 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 134.4M | 138.1M |
| IPO Year | 2023 | 2021 |
| Metric | AMTX | BMEA |
|---|---|---|
| Price | $1.96 | $1.18 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 6 |
| Target Price | ★ $12.00 | $9.83 |
| AVG Volume (30 Days) | ★ 1.1M | 967.2K |
| Earning Date | 05-11-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 32.98 | ★ 69.19 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $77,194,000.00 | N/A |
| Revenue This Year | $49.77 | N/A |
| Revenue Next Year | $57.87 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 174.60 | N/A |
| 52 Week Low | $1.30 | $0.87 |
| 52 Week High | $3.80 | $2.99 |
| Indicator | AMTX | BMEA |
|---|---|---|
| Relative Strength Index (RSI) | 35.60 | 39.71 |
| Support Level | $1.38 | $1.05 |
| Resistance Level | $2.25 | $1.46 |
| Average True Range (ATR) | 0.16 | 0.10 |
| MACD | -0.03 | 0.00 |
| Stochastic Oscillator | 8.63 | 19.74 |
Aemetis Inc is an renewable fuel and biochemicals company focused on the production of renewable fuels and chemicals through the acquisition, development and commercialization of technologies that replace traditional petroleum-based products through the conversion of first-generation ethanol and biodiesel plants into biorefineries. In addition to low carbon renewable fuel ethanol, the Keyes Plant produces Wet Distillers Grains, Distillers Corn Oil, and Condensed Distillers Solubles, all of which are sold to local dairies and feedlots as animal feed. The operations include California Ethanol, California Dairy Renewable Natural Gas and India Biodiesel. It operates in the reportable geographic segments of North America and India.
Biomea Fusion Inc is a a clinical stage diabetes and obesity medicines company focused on the discovery and development of oral, small molecule drugs to treat and improve the lives of patients with diabetes, obesity, and other metabolic diseases. It operate as an organization centered on two of its core drug candidate development programs: (i) icovamenib, its clinical program's drug candidate, currently being developed as an orally bioavailable, and selective, covalent inhibitor of menin in two clinical and multiple preclinical studies, investigating icovamenib's potential in type 1 and type 2 diabetes, as well as its impact in obesity, and (ii) BMF-650, its investigational, next-generation oral glucagon-like peptide-1 GLP-1 receptor agonist in development for the treatment of obesity.